Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01368276 · ClinicalTrials.gov registry record · Phase 3
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
A Phase 3 study, sponsored by BioVex Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 31
- Enrollment target
NCT01368276 is a Phase 3 study that has completed, run by BioVex Limited. The registered enrollment target is 31 participants.
The verdict
NCT01368276, a Phase 3 study, has completed, sponsored by BioVex Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study is to learn about the safety and the risks of using talimogene laherparepvec in patients who already received treatment with talimogene laherparepvec in study 005/05 (NCT00769704), and to see if extended treatment with talimogene laherparepvec can destroy melanoma tumors.
Interventions
- BIOLOGICAL Talimogene Laherparepvec
- DRUG Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2010-10 |
| Est. Completion | 2014-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01368276
The ClinicalTrials.gov registry entry for NCT01368276 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioVex Limited, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Talimogene Laherparepvec is the first listed.
NCT01368276 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01368276 about?
NCT01368276 is a clinical study titled "An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma". The purpose of this study is to learn about the safety and the risks of using talimogene laherparepvec in patients who already received treatment with talimogene laherparepvec in study 005/05 (NCT00769704), and to see if extended treatment with talimogene laherparepvec can destroy melanoma tumors.
What is the current status of trial NCT01368276?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 31 participants. The study started on 2010-10. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01368276?
The interventions under investigation include: Talimogene Laherparepvec (BIOLOGICAL), Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) (DRUG).
Who is sponsoring clinical trial NCT01368276?
This trial is sponsored by BioVex Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.